Volume 14, Issue 1 (2011)                   mjms 2011, 14(1): 59-69 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Farshdousti Hagh M, Noruzinia M, Mortazavi Y, Soleimani M, Kaviani S, Mahmoodinia Maymand M. Epigenetic changes of RUNX2 and DLX5 genes in osteoblastic differentiation induced by zoledronic acid in mesenchymal stem cells. mjms. 2011; 14 (1) :59-69
URL: http://mjms.modares.ac.ir/article-30-7995-en.html
1- Department of Hematology, Faculty of Medical Sciences,Tarbiat Modares University, Tehran, Iran, Tehran
2- Assistant Professor, Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
3- Associated Professor, Department of Pathology, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan
4- Assistant Professor, Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran, Tehran
5- Sarem Cell Research Center (SCRC), Tehran, Iran, Tehran
Abstract:   (5570 Views)
Objective: Zoledronic acid as a main treatment for osteoporosis has an important role in differentiation of mesenchymal stem cells. However, mechanism of osteoblastic differentiation induction by zoledronic acid is not well understood until now. In this research we evaluate zoledronic acid effect on methylation status of RUNX2 and DLX5 promoters. Materials and Methods: After isolation and expansion of hMSCs from BM, they were pulse treated with 5μM ZA for 3h, and incubated in osteogenic differentiation medium for 3 weeks. DNA was extracted after first, second and third weeks of culture and also from undifferentiated MSCs. After SBS treatment, gene specific methylation analysis for RUNX2 and DLX5 were carried out by MSP using methylated and unmethylated primers. Results: In the genes RUNX2 and DLX5, M and U primers of MSP amplified promoter regions of undifferentiated and osteoblastic differentiated MSCs. Therefore, methylation status in RUNX2 and DLX5 promoters present incomplete methylation. Conclusion: Methyltion patterns of RUNX2 and DLX5 don’t change during zoledronic acid osteoblastic differentiation of MSCs. Our findings show that zoledronic acid does not induce osteoblastic differentiation via epigenetic mechanisms. Therefore, zoledronic acid can induce osteoblastic differentiation in a manner independent from DNA epigenetic changes.
Full-Text [PDF 1173 kb]   (3988 Downloads)    
Article Type: Original Manuscipt | Subject: Medical Genetics
Received: 2011/01/21 | Accepted: 2011/03/1
* Corresponding Author Address: Tehran

Add your comments about this article : Your username or Email:
CAPTCHA